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Abstract. Differentiation of pluripotent stem cells, PSCs, towards neural lineages has attracted signiﬁcant
attention, given the potential use of such cells for in vitro studies and for regenerative medicine. The
present experiments were designed to identify bioactive peptides which direct PSC differentiation
towards neural cells. Fifteen peptides were designed based on NCAM, FGFR, and growth factors
sequences. The effect of peptides was screened using a mouse embryonic stem cell line expressing
luciferase dual reporter construct driven by promoters for neural tubulin and for elongation factor 1. Cell
number was estimated by measuring total cellular DNA. We identiﬁed ﬁve peptides which enhanced
activities of both promoters without relevant changes in cell number. We selected the two most potent
peptides for further analysis: the NCAM-derived mimetic FGLL and the synthetic NCAM ligand,
Plannexin. Both compounds induced phenotypic neuronal differentiation, as evidenced by increased
neurite outgrowth. In summary, we used a simple, but sensitive screening approach to identify the
neurogenic peptides. These peptides will not only provide new clues concerning pathways of
neurogenesis, but they may also be interesting biotechnology tools for in vitro generation of neurons.
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INTRODUCTION
Neural differentiation of pluripotent stem cells (PSCs)
has become a topic of major interest in contemporary
biomedical research (1,2). From a basic science point of view,
PSC neural differentiation recapitulates key steps of embryo-
genesis and fetal development, giving unprecedented access
to the underlying mechanisms (3). Therefore, PSC-derived
neurons have a variety of biotechnology applications. Indeed,
they have an important potential for in vitro use, including
disease modeling (4,5), development of central nervous
system (CNS) drugs (6), and neurotoxicity testing (7). Much
discussed is also the potential of PSC-derived neurons for in
vivo use, in particular cell replacement therapy (8–12).
However, in order to allow PSC-derived neurons to live up
to their biotechnology potential, there is a need for better
tools to direct and control neural differentiation.
Traditionally, growth factors (13), extracellular matrix
proteins (14), and other endogenous neurogenic proteins (15)
have been used to direct neurogenesis of PSCs in vitro
(16,17). This approach is logical because it allows mimicking
physiological steps of neural differentiation; however, there
are limits to the use of whole lengths proteins: they are costly,
tend to be relatively unstable. Also, if proteins are supposed
to be further developed for an in vivo use, they have major
limitations, in particular cross of the blood brain barrier, and
potential of immunogenicity (indeed, the adult organism may
recognize as non-self proteins which are only expressed
during embryonic development (18)). For these reasons,
there have been increasing efforts to develop small molecules
that mimic growth factor actions, but would not have the
limitations of the latter (19–21). There are good examples for
a successful application of this approach, for example the so-
called dual Smad inhibition (22) or Notch inhibition through
gamma-secretase inhibitors (23). However, the speciﬁcity of
small molecule inhibitors is often limited and they have a
potential for unpredictable toxicity (24). The use of peptides
as biological drugs potentially combines the advantages of
both approaches described above. Similar to physiological
proteins, small peptides can be designed to act within
developmentally relevant protein networks. Yet because of
their much smaller size, they can be synthesized at lower cost
with higher stability and high chemical and biological
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diversity can be achieved. Also they are not immunogenic.
Peptides often act through physiological receptor pathways
and therefore induced rapid activatory or inhibitory re-
sponses. Basically, there are two approaches to the discovery
of bioactive peptides: screening of randomly generated large
peptide libraries or generation of targeted peptide libraries
based on known bioactive sequences within proteins.
During the embryonic development, the neural cell
adhesion molecule (NCAM) plays an important role in
neurogenesis. It is critically involved in proliferation, migra-
tion, survival, and differentiation of neural progenitors (25).
NCAM is able to interact with itself through both homophilic
cis- and trans-interactions forming zipper-like complexes.
NCAM binds to several heterophilic ligands as well, like:
the ﬁbroblast growth factor receptors (FGFRs), the glial cell
line-derived neurotrophic factor (GDNF), and its cognate
receptor, GDNF family receptor α (GFRα) among others
(26). Besides brain-derived neurotrophic factor (BDNF),
nerve growth factor (NGF), the last decade of research has
dramatically widened the picture of the functional roles of
NCAM showing that NCAM is a multifunctional regulator of
cell adhesion, intracellular signaling, and cytoskeletal dynam-
ics, all phenomena of key importance in stem cell differenti-
ation (27). Based on the structure–function relationship of
NCAM, small peptides mimicking NCAM activities mediated
via its different binding sites were discovered (27–29). For
example, peptides derived from the structure of NCAM and
growth factors induced the neural differentiation in primary
cerebellar granule neurons or hippocampus neurons (29–37).
It was the purpose of this study to investigate neurogenic
properties of small peptides derived from bioactive sequences
within neurotrophic proteins. The initial screen was performed
with a dual promoter/reporter line (derived from mouse
embryonic PSCs). Key results were conﬁrmed by immunoﬂuo-
rescence and neurite outgrowth assays. Among 15 peptides
investigated in this study, at least two were found to have potent
neurogenic activity during PSCs differentiation. Our results
indicate that a peptide design based on bioactive sequences of
relevant proteins, such as NCAM or related growth factors,
represents a promising approach for the understanding and
control of neural differentiation.
MATERIALS AND METHODS
Peptides
All peptides were synthesized by Peptides&ElephantsGmbH
(Potsdam, Germany). Peptides were synthesized using the Fmoc-
protection strategy on TentaGel resin using Fmoc-protected amino
acids. The peptides were synthesized in two forms: (a) dimeric
peptides composed of two linearmonomers linked together by aC-
terminal lysine residue (FGLL, FGLs, Inherbin3, EncaminA,
EncaminC,EncaminE, andGliaﬁn), and (b) tetrameric dendrimers
composed of four monomers coupled to a lysine backbone
(Betroﬁn3, Betroﬁn4, C3, P2, Plannexin, hNgf_C2, hNgf_E, and
hNgf_EE; 29–38; see overview of peptides in Table I). Peptides
were at least 85% pure as estimated by mass spectrometry and
analytical high-performance liquid chromatography (HPLC). The
peptides were dissolved in MilliQWater, and the concentrations of
peptides were determined spectrophotometric by measuring the
absorption at 205 nm (39).
Reagents
Murine CGR8 ES cell line was purchased from European
Collection of Cell Culture. The human embryonic stem (hES) H1
was obtained from WiCell Research Institute, Inc., WA01. The
bone marrow stromal MS5 cell line was kindly provided by
Katsuhiko Itoch (40). Cell culture medium, fetal bovine serum,
knockout serum replacement, penicillin/streptomycin, N2 supple-
ment, non-essential amino acid, sodium pyruvate, FGF2, and
FGF8 were purchased from Gibco, Invitrogen Corporation
(Paisley, Scotland). Dual-luciferase® Reporter Assay System
was from Promega (Madison, WI, USA); Poly-L-ornithine was
from Sigma-Aldrich. Antibody and dilution were as follows:
rabbit anti-βIII-tubulin (1:2,000; Covance, Princeton, NJ, USA).
The ﬂuorochrome-coupled secondary antibody was used,
AlexaFluor® 555 Goat Anti-rabbit (1:1,000; Invitrogen-
Molecular Probes).
Mouse ES Cell Culture
Dual luciferase expressing CGR8-2luc cells were obtained
by transduction of mouse ES CGR8 cells with the 2 k7 EF1-αS
Rluc/Tα1α Fluc vector as previously described (41,42). EF1-αS
corresponds to the short promoter of the eukaryotic translation
elongation factor 1 alpha 1 (EEF1A1) and Tα1α to the Tubulin
alpha1 (TUBA1A) promoter. Cells were cultured on 0.1%
gelatin-coated dishes in CGR8-2luc maintenance medium:
BHK21 medium, 10% fetal bovine serum (FBS), 2% sodium
pyruvate, 1% non-essential amino acids, 2 mM L-glutamine,
beta-mercaptoethanol (0.1 μM), 1% penicillin/streptomycin,
and leukemia inhibitory factor LIF (43). CGR8-2luc cells grow
in a feeder-independent manner and therefore no murine
embryonic ﬁbroblasts (MEFs) or other feeder cells were used.
CGR8-2luc Differentiation and Exposure to Peptides
The overview schemes of differentiation protocols (proto-
col 1 and 2) were shown in Fig. 1. For the primary screening
assay, cells were cultured as described previously (42). Brieﬂy,
103 CGR8-2luc cells per well were plated on gelatin-coated 96-
well plates in differentiation medium: BHK21 medium, 20%
FBS, 2% sodium pyruvate, 1% non-essential amino acids, 2 mM
L-glutamine, beta-mercaptoethanol (0.1 μM), 1% penicillin–
streptomycin; 48 h later, the medium was removed and replaced
by 300 μl fresh differentiation medium with various
concentrations of growth factors, peptides, or solvent control.
Seventy-two hours later, cells were assayed for Fireﬂy and
Renilla luciferase activity.
To perform the neurite elongation assay, neuronal differen-
tiation was carried out as described (42,44). Brieﬂy, irradiated
MS5 cells (1.75×105 per well) were seeded in 6-well plates. The
next day, CGR8-2luc cells (0.6×103 to 3×103 cells per well) were
plated on the MS5 layer in SR medium (DMEM high glucose
supplemented with 15% knockout serum, non-essential amino
acids, 2-mercaptoethanol, Pen/Strep) for 5 days with growth
factors, peptides, or solvent control found in the primary screen.
Five days later, cells were then trypsinized and seeded 1,000 cells/
well onto polyornithine-coated 24-well plates in N2 medium
(DMEMhigh glucose, N2 supplement with 10 ng/ml human basic
ﬁbroblast growth factor, Pen/Strep) and cultured for four
additional days without compounds addition.
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Dual-Luciferase Assay
Luciferase activity was measured with Dual-luciferase®
Reporter Assay System kit. CGR8-2luc ES cells were lysed in
96-well plates according to the manufacturer’s instructions.
Luminescence measurements were performed in triplicates
on Fluostar Optima reader (BMG Labetch GmbH,
Germany). Luminescence counts were normalized by com-
parison to the control wells without treatment after subtrac-
tion of the background luminescence.
Propidium Iodide and Resazurin (AlamarBlue®) Assay
DNA quantity was determined by Propidium iodide (PI).
Propidium iodide was added to cell homogenates after lucifer-
ase test, at a ﬁnal concentration of 50 μg/ml and incubated for an
additional 2 h. After incubation, the ﬂuorescence intensity was
measured with a Fluostar Optima microplate reader (excitation
544 nm±15 nm, emission 620 nm±15 nm).
Cell viability was determined using alamarBlue®
(Invitrogen, Carlsbad, CA92008, USA). In brief, CGR8-2luc
cells were seeded in 96 wells at a non-conﬂuent cell density and
incubated for 24 h under standard cell culture conditions. After
4 h of exposure to Methylmercury (MeHg), 20 μl of
alamarBlue® solution (diluted 1:10 from stock solution) was
added to each well. After a 2-h incubation at 37°C, ﬂuorescence
was measured (excitation 544 nm, emission 590 nm) and
corrected to background control (no cells). Results are given
as fractional survival as compared to untreated cells.
Human ES Cell Culture
The human embryonic stem (hES) cells H1 (WiCell
Research Institute, Inc., WA01) cell line was maintained on
irradiated MEFs freshly isolated from mouse 13.5 dpc embryos
(C57BL/6 strain). The hES cells cultures were fed daily DMEM/
F12 glutamax supplemented with 20% knockout serum replace-
ment, 1mMnonessential amino acids, 1%penicillin/streptomycin,
0.55 mM 2-mercaptoethanol, and 5 ng/ml recombinant human
FGF2. hES cells were enzymatically treated with collagenase for
passaging every 5–7 days.
Neural Differentiation of H1 hESC Line
Neural induction of H1 hES cell line was based on dual
SMAD inhibition, slightly modiﬁed from (45). The overview
scheme of differentiation protocol 3 was shown in Fig. 1. Brieﬂy,
undifferentiated hESC colonies were starved in N2B27 medium
supplemented with FGF2 (5 ng/ml, Invitrogen). The next day
H1 hES cells were manually detached from the feeder-layer,
collected in differentiation medium composed of N2B27 medi-
um and transferred for 6 h to low-attachment plate. Cells were
Table I. Overview of the Peptides
Peptide Molecular weight Sequence Modiﬁcation
FGLL 3,396.7 EVYVVAENQQGKSKA Dimer
FGLs 2,413.7 VAENQQGKSKA Dimer
Inherbin3 4,265.04 LVYNKLTFQLEPNPHTK Dimer
EncaminA 3,884 SIDRVEPYSSTAQVQFD Dimer
EncaminC 3,752.2 KAEWKSLGEEAWHSK Dimer
EncaminE 3,270 TIMGLKPETRYAVR Dimer
Gliaﬁn 3,888.6 ETMYDKILKNLSRSR Dimer
Betroﬁn3 5,995.82 RGIDKRHWNSQ Dendrimer
Betroﬁn4 8,679.5 SYVRALTMDSKKRIGWR Dendrimer
C3 5,363.77 ASKKPKRNIKA Dendrimer
P2 5,904.18 GRILARGEINFK Dendrimer
Plannexin 5,151.3 DVRRGIKKTD Dendrimer
hNgf_C2 6,075.74 ETKCRDPNPVDSG Dendrimer
hNgf_E 5,859.58 RGIDSKHWNSY Dendrimer
hNgf_EE 7,699.31 TFVKALTMDGKQAAWR Dendrimer
Fig. 1. Overview scheme of the differentiation protocols. Protocol 1
is the primary screening assay. CGR8-2luc cells per well were plated
on gelatin-coated 96-well plates in differentiation medium. Forty-
eight hours later, the medium was removed and replaced by peptides.
Seventy-two hours later, cells were assayed for Fireﬂy and Renilla
luciferase activity. Protocol 2 is the neurite outgrowth assay. CGR8-
2luc cells were cocultured on MS5 cells with peptides exposure for
5 days. Five days later, cells were then seeded on polyornithine-
coated plates and were cultured for four additional days without
compounds addition. Protocol 3 is the human ESC neural differen-
tiation morphology assay. The obtained neural stem cells from dual
SMAD protocol, cells were cultured on laminin-polyornithine-coated
plates with peptides exposure from day 12 to day 24
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then seeded on 300 ng/cm2 poly-ornithine (Sigma) and 500 μg/
cm2 laminin (Trevigen) sequentially coated tissue culture plates.
Differentiationmediumwas changed after 24 h then every other
day. LDN193189 (1 μM, Axonmedchem) and SB431542
(20 μM, Tocris Biosciences) were added from day 0 and on for
every medium change until rosette neural stem cell (R-NSC)
arose at day 8 to 12. R-NSC were manually collected at day 10–
14, enzymatically detached using 0.05% trypsin (Invitrogen),
and seeded at 105 cells/cm2 on polyornithine and laminin-coated
tissue culture plates in N2B27 medium supplemented with
FGF2 (10 ng/ml, Invitrogen), EGF (10 ng/ml, R&D systems).
Cells were maintained in the same medium and passaged every
2–3 days for no more than 25 passages.
Immunoﬂuorescence Analysis
Immunostaining with rabbit anti-βIII-tubulin and Alexa
Fluor 555-conjugated anti-rabbit IgG secondary antibody was
performed as described previously (42). In brief, cells plated
on polyornithine-coated glass cover slips were ﬁxed with 2%
PFA, permeabilized with 0.5% (v/v) Triton X-100 and stained
for Tubulin and counterstained with DAPI to visualize the
nucleus. Negative control immunostaining was performed
without ﬁrst antibody. After wash with PBS, coverslips were
mounted on glass slides using FluorSaveTM Reagent
(Calbiochem, San Diego, CA, USA).
Determination of Neurite Elongation
Images were acquired on a Mirax Micro digital slide
scanner (Carl Zeiss) or a Zeiss axioplan microscope equipped
for epiﬂuorescence. Immunostaining and nuclear staining
quantiﬁcations were performed using the Mirax Viewer
(Carl Zeiss) and MetaXpress (Molecular Devices) software
with the following settings of cell body recognition: min width
4 μm, max width 28 μm, 40 gray levels above background.
Total neurite outgrowth was quantiﬁed using the neurite
outgrowth analysis module, and total cell numbers were
quantiﬁed with the count nuclei analysis module.
Peptide Stability Assay
Peptides were dissolved in FBS (270 μl) to a concentra-
tion of 0.2 mM (30 μl of 2 mM) and incubated at 37°C.
Fig. 2. Correlation between ﬂuorescence and cell count. Cells were grown for 24 h under
undifferentiation and differentiation conditions at 37°C and were subsequently tested in a
96-well plate (200 μl ﬁnal volume). a Numbers of CGR8 cells were cultured in maintenance
medium for 24 h, PI was added to each well (ﬁnal concentration in well 50 μg/ml), and
ﬂuorescence was determined after 2 h incubation. b 200×103 CGR8 cells in differentiation
medium were cultured with Methylmercury for 48 h, PI was added to each well (ﬁnal
concentration in well 50 μg/ml), in which the cells were incubated for 2 h at 37°C, and after
which ﬂuorescence was determined. c 200×103 CGR8 cells in differentiation medium were
cultured with Methylmercury for 48 h. Each well was added 20 μl of 10× resazurin in PBS.
Fluorescence was determined after 2 h 37°C incubation
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Aliquots (30 μl) were removed at various time intervals and
quenched with aq. 60 μL trichloroacetic acid (5%). The
aliquots were vortexed and incubated for 15 min at 4°C prior
to centrifugation at 18,000×g for 2 min. The supernatants
were analyzed by RP-HPLC to quantity peptide relative to
time zero.
Fig. 3. Effect of cognate ligands of FGF receptor on CGR8-2luc neural differentiation. a, b Dual luciferase
activity of FGF2 and FGF8 in CGR8-2luc cells. CGR8-2luc were grown on 0.1% gelatin for 48 h, afterwards
continued to culture in the presence of the indicated concentrations of FGF2 or FGF8 for 72 h. Cells were
subsequently tested a Fireﬂy, b Renilla luciferase activity, and c DNA quantity by PI assay. Results are
expressed as percentages±SEM with untreated controls set at 100%. Error bars indicate SEM based on
three independent experiments. d Effect of FGF2 and FGF8 on neurite extension. CGR8-2luc were grown
on MS5 for 5 days with FGF2 (100 ng/ml) or FGF8 (1 ng/ml) in SR medium. Cells were subsequently
dissociated and replated in N2 medium for additional 4 days without compounds addition. Vehicle, FGF2,
and FGF8-treated ES cells were examined for β-III tubulin (red), and nuclei were stained with DAPI (blue)
on day 9 of differentiation. **P<0.01, ***P<0.005, compared with untreated cells (control; Student’s paired
t test)
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Statistical Analysis
The data were plotted as mean (SEM from three
independent experiments. Statistical signiﬁcance was ac-
cepted at p<0.05. The results were analyzed with one-way
analysis of variance (ANOVA) or t test using Prism 5
software (GraphPad Software, San Diego, CA).
RESULTS
Propidium Iodide Fluorescence as an Approximation of Cell
Number
The dual reporter line detects the activity of a Tα1
promoter fragment and an EF1-α promoter fragment. The
initial concept of this promoter construct was to use the Tα1
promoter as a reporter for neural differentiation and the
EF1-α promoter as a house keeping promoter that would
reﬂect the cell number. However, as published previously
(46), the EF1-α promoter is responsive to cell differentiation
(down-regulation) and to neuroactive and neurotoxic com-
pounds (upregulation or downregulation). Thus, while the
EF1-α promoter activity contributes to ﬁngerprinting of the
effect of a compound on neural differentiation, it does not
provide information about the number of cells. We have
therefore added a novel parameter to our neural differen-
tiation assay, namely propidium iodide (PI) ﬂuorescence.
This assay is performed by adding PI to cell homogenates
after the luciferase assays is performed. To validate the
assay, we ﬁrst investigated the correlation between cell
number (undifferentiated CGR8 cells) and the PI ﬂuores-
cence. As shown in Fig. 2a there is a good correlation. To
study the behaviour of the assay in a more complex
situation, we investigate neurotoxicity of Methylmercury
comparing the classical cytotoxicity assay Alamar blue with
our PI assay. As shown in Fig. 2 (panel b and c) the PI
assay correlated well with the Alamar blue assay. Thus, we
conclude that the PI assay provides an approximation of the
cell number in our assay system. Of importance, the assay is
readily combined with the dual luciferase assay and PI
measurement can be performed in the same homogenates
used for measuring luciferases activity.
Effect of Growth Factors in the Assay System
To validate our assay system, we analyzed the effects
of two growth factors FGF2 and FGF8. We ﬁrst investi-
gated their impact in a spontaneous differentiation assay,
based on culture of CGR8-2luc cells in a basal neural
differentiation medium (see Methods). A 3-day exposure
of cells to FGF8 led to increased Tα1 and EF1-α
promoter activities without a signiﬁcant effect on the PI
signal (Fig. 3a–c). A similar tendency, however without
statistical signiﬁcance was observed for FGF2. We next
investigated the impact of the growth factors in a stroma
cell-enhanced differentiation assay. Figure 3d shows im-
munoﬂuorescence analysis of FGF2- and FGF8-treated
differentiated CGR8-2luc cells. These results show that
both growth factors, in particularly FGF8, enhance neurite
outgrowth in differentiating CGR8-2luc cells (for quanti-
ﬁcation see below).
Primary Screen of Bioactive Peptides
Peptides derived from growth factors could mimic the
effect of growth factors or even be more efﬁcacious. We have
therefore used peptides designed based on well-deﬁned regions
of NCAM, BDNF (brain-derived neurotrophic factor), GDNF
(glial cell derived neurotrophic factor), NGF (nerve growth
factor), FGFR (ﬁbroblast growth factor receptor), and EGFR
(epidermal growth factor receptor). Schematic representations
of the origins of the peptide sequences are shown in Fig. 4.
These putatively bioactive peptides were investigated using
the neural differentiation assays described above. Dose–
response analysis ranging from 10 nM to 100 μMwas performed
for all peptides, and Tα1 and EF1-α promoter activities, as well
as DNA content were measured (Figs. 5 and 6). The obtained
results allowed grouping the peptides into three categories,
based on their responses in the dual luciferase assay: group 1
had no effects or even showedmild inhibitory effect; for group 2,
effects were only observed at 100 μM; for group 3, a dose–
response was observed starting from either 3 or 10 μM.Group 1
comprises 4 NCAM-derived peptides (FGLs, EncaminA,
Encamin C, P2) and 2 NGF-derived peptides (hNgf_C2,
hNgf_EE). Obviously group 1 is not of further interest for our
Fig. 4. Schematic showing positions in NCAM, BDNF, NGF, GDNF,
and EGFR of the various bioactive peptides described in this study
Fig. 5. Effect of peptides derived from NCAM on CGR8-2luc neural
différentiation. CGR8-2luc were grown on 0.1% gelatin for 48 h and
continued to culture in the presence of the indicated concentrations (0.01–
100 μM) of FGLs, FGLL, EncaminA, EncaminC, EncaminE, C3, P2, and
Plannexin for 72 h. Cells were subsequently tested a, d, g, j, m, p, s, v
Fireﬂy, b, e, h, k, n, q, t, w Renilla luciferase activity, and c, f, i, l, o, r, u, x
DNAquantity. Results are expressed as percentage±SEMwith untreated
controls set at 100%.Error bars indicate SEMbased on three independent
experiments. *P<0.05, **P<0.01, ***P<0.005, compared with controls
(one-way, repeated-measures ANOVA, Bonferroni’s post hoc test)
b
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Fig. 6. Effect of peptides derived from BDNF, EGFR, NGF, and GDNF on CGR8-2luc neural differentiation. CGR8-2luc were grown
on 0.1% gelatin for 48 h, and continued to culture in the presence of the indicated concentrations (0.01–100 μM) of Betroﬁn3, Betroﬁn4,
Inherbin3, hNgf_C2, hNgf_E, hNgf_EE, and Gliaﬁn for 72 h. Cells were subsequently tested a, d, g, j, m, p, s Fireﬂy, b, e, h, k, n, q, t
Renilla luciferase activity, and c, f, i, l, o, r, u DNA quantity. Results are expressed as percentage±SEM with untreated controls set at
100%. Error bars indicate SEM based on three independent experiments. *P<0.05, **P<0.01, ***P<0.005, compared with controls
(one-way, repeated-measures ANOVA, Bonferroni’s post hoc test)
407Neuroactive Peptides of Embryonic Stem Cells
studies, however it provides an important control, as it excludes
that peptide addition has non-speciﬁc effects in our experimen-
tal system. Group 2 comprises one NCAM-derived peptide
(EncaminE) and two BNDF-derived peptides (Betroﬁn 3,
Betroﬁn 4) and one NGF-derived peptide (Glaﬁn). This group
might have some effect on neural differentiation; however, as
these effects are observed only at very high concentrations, it is
difﬁcult to exclude that the effects are non-speciﬁc and we have
therefore not further investigated this group. Group 3 comprises
three NCAM-derived peptides (FGLL, C3, and Plannexin), one
EGF-derived peptide (Inherbin 3) and one NGF-derived
peptide (hNgf_E). This group is obviously of most interest for
future work on neural differentiation. For all these peptides,
there was (a) a parallel increase in Tα1 and EF1-α promoter
activities and (b) a decrease in total DNA content (i.e., cell
number). FGLL was the most potent compound and elicited
effects on Tα1 and EF1-α promoter activities already at 3 μM.
Also, while most of the active peptides enhanced Tα1 and EF1-
α promoter activities to a similar extent, FGLL had a preferen-
tial impact on the neuronal Tα1 promoter. The C3 peptide also
was relatively potent, showing activity in our assay starting from
10 μM; however as opposed to FGLL, it did not have a
preferential activity on neuronal Tα1 promoter. Indeed, its
effects appeared slightly more pronounced on the ubiquitous
EF1-α promoter. Also, the effect onDNA content was relatively
modest, as compared to the one seen with FGLL. Inherbin3 and
hNgf_E have effects resembling these of the C3 peptides,
however slightly less potent. The responses to Plannexin show
unique features. Its activity, similar for Tα1 andEF1-α promoter
activities, starts only at 30 μM, however decreases at 100 μM,
and even the DNA content appears decreased to a lesser extend
at 100 μM as compared to 30 μM.
Peptide Stability
For the three most active peptides, FGLL, Plannexin, and
C3, we measured peptide stability. For this purpose, peptides in
aqueous solution were kept at 37°C, and samples for HPLC
analysis were taken after 2, 8, 24, 48, and 96 h. As shown in
Fig. 7, C3wasmost stable and approximately 50%of the peptide
was still detected after 96 h. Plannexin showed an intermediate
stability, with a half life of approximately 28 h. Finally, and
unexpectedly, the most active compound, FGLL, had only a
relative short half life of approximately 6 h.
Impact of Peptides on Neurite Outgrowth
Next we investigated the effect of two active peptides,
FGLL and Planexin, on neural maturation by investigating
the capacity of neural progenitor cells (NPCs) to extend
neurites. As neurite extension requires a relatively high degree
of NPC differentiation, cells were differentiated for 5 days in
coculture with MS5 cells (44), and compounds of interest were
added during this differentiation phase. Neurite extension was
investigated during a 4 day culture on polyornithin-coated
plates, after the 5 day differentiation protocol. Thus, we have
investigated the effect of the peptides on NPC maturation, and
not a direct effect on neurite extension. As a positive control, we
chose phenazopyridine, a neurogenic small molecule that we
have previously shown to enhance neurite outgrowth (42). We
chose the P2 peptide as negative control; as in the primary
screen, it was found not to enhance neural differentiation and
even had a moderate inhibitory effect (Fig. 5). As can be seen in
Fig. 8, FGLL and Plannexin, at concentrations of 30 μM
(number of surviving cells after exposure to FGLL and
Plannexin: 4.38±0.4×105, 4.42±0.3×105) and 100 μM (number
of surviving cells after exposure to FGLL and Plannexin: 4.27±
0.3×105, 4.31±0.4×105) caused an increase of neurite
outgrowth, as compared to control (number of surviving cells,
4.2±0.4×105) and P2 peptide (number of surviving cells, 4±0.2×
105). Automated imaging of neurite outgrowth (MIRAX)
conﬁrmed the visual impression: both FGLL and Plannexin
enhanced neurite outgrowth. For comparison, the effect of the
full length growth factors FGF2 and FGF8 are included in the
quantitative analysis (for pictures see Fig. 3). Interestingly, the
peptides were more powerful than the growth factors in this
system, which corroborates data obtained with the dual
luciferase assay (compare Figs. 3 to 5).
Effect of FGLL on Neural Differentiation of Human ES Cells
We next determined the effect of the most powerful
peptide, FGLL, on neural differentation of human ES cells.
H1 human ESCs were differentiated according to standard
protocols (Methods) and FGLL (30 and 100 μM) was added
daily from day 1 to day 10 of the differentiation protocol. As
can be seen in Fig. 9, light microscopic analysis performed at
day 18, showed homogenously appearing, evenly spread cells
under control conditions. In contrast, cultures in the presence
of FGLL were more mature, with polarized individual cells
migrating outwards from spherical clusters. Individual cells
displayed multiple neurite outgrowths, in particular with the
higher concentrations of FGLL. Immunostaining with β III
tubulin antibodies and counterstaining with DAPI (day 24)
revealed more abundant nuclei under control conditions, but
more abundant β III tubulin-positive neurites in cells treated
with FGLL. The density of the neurite network appeared to
be increased with the higher FGLL concentration.
DISCUSSION
In this study, we have investigated the effect of peptides,
derived from proteins within neural growth factor pathways,
on early neural differentiation. We have performed an initial
screen in a mouse ES cell dual reporter gene expression
Fig. 7. In vitro stability in serum at 37°C for dimeric peptide FGLL
and dendrimeric peptides Plannexin and C3. Half-lives (T1/2[h]) are
shown in parentheses (±SEM)
408 Xu et al.
assay. The peptide with the most potent efﬁcacy on neural
differentiation was FGLL, a peptide derived from the neural
adhesion molecule NCAM. FGLL enhanced neural promoter
activity at low micromolar concentrations, enhanced neurite
outgrowth and enhanced neural differentiation.
Stem cell-based neuronal systems for in vitro testing are
becoming increasingly important for the detection of neurotoxic
and neuroactive compounds (47–49). We have recently de-
scribed and validated a stem cell based dual luciferase reporter
assay for neuronal in vitro testing (42,46). To overcome certain
Fig. 8. Effect of Phenazopyridine, P2, FGLL, and Plannexin in neuronal differentiation on CGR8-2luc. CGR8-2luc were
grown on MS5 for 5 days with compounds of indicated concentrations in SR medium. Cells were subsequently dissociated
and replated in N2 medium for additional 4 days without compounds addition. Vehicle and Phenazopyridine, P2, FGLL, and
Plannexin-treated ES cells that examined for β-III tubulin (red) and nuclei were stained with DAPI (blue) at day 9 of
differentiation. Results are expressed as ratio of total neurite outgrowth and total cell numbers±SEM with untreated
controls. Error bars indicate SEM based on three independent experiments. *P<0.05, **P<0.01, compared with controls
(one-way, repeated-measures ANOVA, Bonferroni’s post hoc test)
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limitations of our assay, we have now developed a novel
parameter to our neural differentiation assay, which can be
readily performed after the dual luciferase assay. It quantiﬁes
the total amount of DNA and therefore serves as a convenient
approximation of the cell number.We have compared the PI test
to other test investigating cell number and cytotoxicity (Fig. 3)
and found it to be robust and reliable.
To understand the impact of the peptides on the dual
reporter assay, we ﬁrst studied the impact of the two growth
factors FGF2 and FGF8. These results show that FGF8
enhances neural differentiation as demonstrated by the in-
creased Tα1 promoter activity. However, while neural differen-
tiation is generally accompanied by a decrease in EF1-α
promoter activity (presumable because of a decreased need of
protein synthesis in post-mitotic differentiated neurons, (46)),
FGF8 increased EF1-α promoter activity. This concomitant
activation of the neural promoter and the house-keeping
promoter is, in our hands, a signature proﬁle for growth-factor
like activity. This is in line with the results observed with PI
analysis. Indeed, none of the two growth factors FGF2 and
FGF8 enhanced cell number when added during neural
differentiation. This is most likely due to the fact that the
selected growth factors induced at the same time NPC
proliferation and neural differentiation (which leads to cell
cycle arrest as mature neurons are postmitotic), which would
account for the absence of an effect on cell number.
Out of the 15 peptides analyzed in the study, ﬁve were
considered to be neuroactive. Interestingly all of those ﬁve peptides
induced an increase in Ta1 and in EF1a promoter activity. In this
respect, they resemble the effect of the growth factor FGF8.
Interestingly, the activity pattern observedwith the ﬁve neuroactive
peptides also resembles the pattern observed with several antide-
pressants in the dual luciferase assay (46). And indeed, recent data
suggest that antidepressants might exert their therapeutic beneﬁt
through activation of neurogenesis from NSCs (50–53). Further
research will be necessary to understand whether the peptides
described in this study might have antidepressant activity in vivo.
FGLL and Plannexin had the strongest neurogenic
effects in our study. The peptide structure of FGFL and
Plannexin provides possible hints about their targets. First,
both peptides are derived from NCAM. However, FGFL, a
15-amino-acid-long peptide, synthesized to correspond to the
second ﬁbronectin type III module of NCAM (which binds to
FGFR1), mimics the heterophilic binding of NCAM to
FGFR1. Plannexin, a synthetic 10-amino-acid-long peptide,
mimics a homophilic trans-binding site in the NCAM Ig2
module which binds to the other NCAM Ig3 module,
subsequently leading to activation of the FGFR. The
NCAM-derived FGLL peptide is an agonist of the FGFR,
has the direct interaction with FGFR, without prior NCAM
binding (in contrast to Plannexin). Second, the peptides are
capable of binding to speciﬁc extracellular regions of FGFR
or NCAM, with different binding afﬁnity. FGLL binds to
FGFR1 isotype c with an apparent dissociation constant (Kd)
of 2.58±2.06 μM (54), whereas Plannexin binds to the Ig1–2–
3 fragment of NCAM with a dissociation constant (Kd) of
5.07±1.8×10−7 M (31). That might explain distinct effects in
the primary screen: while Plannexin showed an FGF8-like
pattern with an approximately equal activation of the Tα1
and the EF1-α promoter, FGLL preferentially activates Tα1.
Fig. 9. The effect of FGLL on human ES cells neural differentiation. Neural differentiation
after 18 days, cells exhibit increasingly neuritic extensions in the presence of FGLL from 30
to 100 μM under 4 and 40 times magniﬁcation of light microscope (LM). Neural positive
cells were marked with β-III tubulin (red), and nuclei were stained with DAPI (blue) at
day 24 of differentiation under ten times magniﬁcation of ﬂuorescence miscroscope (IF)
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We evaluated the stability of the three most effective
peptides FGLL, C3 and Plannexin in serum and found out the
degradation of dimeric peptide is faster than dendrimeric
peptide. The dimeric peptide FGLL was degraded relatively
fast with half-lives (T1/2) of less than 6 h, but tetrameric
dendrimer Plannexin and C3 composed of four monomers
with the sequence coupled to a lysine backbone led to a ﬁve-
to 13 fold increase in T1/2 in serum. This suggests that
dendrimeric peptides, such as Plannexin and C3, showed
superior stability. Thus, the dendrimerization contributes
more than dimerization per se to stability. A puzzling result
of these experiments is the fact that the least stable peptide is
the one with the highest bioactivity. The most simple
explanation would be that only a short term stimulation is
needed for the effects on neural differentiation and therefore
degradation is not relevant. However, we cannot exclude two
alternative explanations: (a) short-term stimulation is more
powerful than long stimulation and (b) the dimeric peptide is
a more efﬁcient receptor agonist than the tetrameric peptide.
In summary, we have demonstrated that pluripotent stem
cells with a dual reporter system are a powerful tool to investigate
neurogenic effects of peptides. Indeed, peptides are interesting
and potentially powerful tools for pharmacological interventions
in vitro and in vivo. First, peptides are easy to synthesize at
relatively low costs and peptide libraries that display high levels of
chemical and biological diversity can therefore be generated.Also,
as opposed to proteins, small peptides are unlikely to invoke an
immune response since they fall below the immunogenic thresh-
old. However, the biological impact of a peptide cannot be
predicted based on its structure and pharmacological preparation.
Thus, biologically relevant assay systems are required. The
approach described in this study provides such a biologically
relevant, embryonic stem cell based testing system.The system can
be used even for higher throughput screening and is suitable to
analyze larger peptide libraries in the future. Yet, FGLL, identiﬁed
in this study as a potent inducer of neural differentiation is already
a peptide that should merit further attention. Because of its
relatively low stability in serum, it might not be the ideal peptide
for systemic administration in vivo, however it might be an
interesting addition to in vitro neural differentiation protocols.
Also, it might be interesting to think about its potential to be
cotransplanted with ESC-derived neurons for cell therapy
applications.
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